


1/20


Fig. 1



09830647.073001

2/20

Fig.2




09830647.073001

3/20

09/830647


Fig.3



09830647 073001

4/20

Fig. 4




**Fig.5**

1 10 20 30 40 50 60  
MNSGAMRIHSGHFGGGI QVKNEKNRPSLKS LKTDNRPEKSKCKPLWGKVFYLDLPSVTI  
Dbf4 motif-N  
61 70 80 90 100 110 120  
SEKLOKD IKDLGGRV EEF LSKDISYLL SNKKEAKFAOTLGRISPV P SPESAYTAETTSPH  
121 130 140 150 160 170 180  
PSHDGSSFEKSPDTVCLSRGKLLVEKA IKDHD FIPSN SILSNALSWG VKILHIDDIRYYIE  
181 190 200 210 220 230 240  
QKKKELYLLKKSSTSVRDGGKRVGSGAQKTRTGRLKKPFVKVEDMSQLYRPFYLQLTNMP  
241 250 260 270 280 290 300  
FINYSIQKPCSPFDVDPSSM QKOTQVKLRIOTDGD KYGGTSIQ LQLKEKKKKGYCECCL  
Dbf4 motif-C  
301 310 320 330 340 350 360  
QKYEDLETHLLSEQHRNFAQSNQYQVDDIVSKLVDFVEYEKDTPKKKRIKYSVGSLSLP  
361 370 380 390 400 410 420  
VSASVLKKTEQKEKVELQHISQKDCQEDDTTVKEQNFLYKETQETEKLLFISEPIPHPS  
421 430 440 450 460 470 480  
NELRGLNEKMSNKC SMLSTAEDDIRQNFTQLPLHKNKQECILDISEHTLSENDLEELRVD  
481 490 500 510 520 530 540  
HYKCNIQASVHVSD FSTDN SSGSQPKQKSDTVLFP AKDLKEKDLHSIFTHDSGLITINSSQ  
541 550 560 570 580 590 600  
EHLTVQAKAPFHTPPEEPNECDFKNMDSLPSGKIHRKVKIILGRNRKENLEPNAEFDKRT  
601 610 620 630 640 650 660  
EFITQEENRICSSPVQSLDLFQTSEEKSEFLGFTSYTEKSGICNVLDIWEENE S D NLLT  
661 670 674  
AFFSSPSTSTFTGF\*

6/20

Fig.6



## Dbf4 motif-N

H37 32: LKTDNREKSKGKPLWGRFYLDLPSVITSEKLOKDTKDLGGRVEEFLSKDISYLTISNKK 91

mu-H37 : LKADNRLEKSKYKPLMGKIFYLDLPSITICEKLOKDTKELGGRVEEFLSKDISYFVSNKK

Dm-H37 : TPPKVKVIKSK-RPLCHFKFYLLICDHQLAKRIESDINALGGHLEFFLSDDITHFVTKRP

\*\*\* \*\* \*\*\*\* \*\*\* \*\* \*

huDbf4N 92: EAKFAQT 98

muDbf4N : EAKYAQT

DmDbf4N : IVIGGTS

\*

## Dbf4 motif-C

H37 263: KQTQVKLRIQTDGDKYGGTSIQLQLKEKKKGYCECCLOKYEDLETHILSEQHRNFAQSN 322


mu-H37 : KQAQPKLRINMDGDKC-GIPVQLQLKEKRRKKGYCECCLOKYEDLETHILSEKIRNFAQSN

Dm-H37 : PSLQELKKQSAIPNSPRSNCREPIDSSERQCGVCEIGKLEYDILNTHILOSKDHELFANSS

Dbf4 619: KKSTSTNVTLHFNAQTAQIAQPVKKETVKNNGYCHNGRVKYESLEQHLVSLKHLSPAE-N 677


\*\*\* \* \* \* \* \*

**Fig.7**



8/20


Fig.8






9/20

Fig.9




10/20

Fig. 10



11/20


Fig. 11



09830647.073001


12/20

Fig. 12



13/20




Fig.13



09830647.073001

14/20


Fig.14



15/20

Fig. 15

1 (G2/M)




2 (6h)



3 (12h)






4 (18h)



09830647.073001

16/20







Fig.16





17/20


Fig.17



09830647.073001

18/20


Fig.18

%BrdU-Positive  
Cells

09830647.073001

19/20

Fig.19



T00E20" 2490E860

20/20

Fig.20

Microinjection with

